Ferring Pharmaceuticals, a Parsippany-based biopharmaceutical firm, announced on Monday that Brent Ragans has been appointed president.
In this role, Ragans will be tasked with overseeing the company’s commercial, manufacturing and development of Ferring in the U.S. He will report to Aaron Graff, global chief commercial officer.
“Ferring is entering a new phase in which it will expand its leadership in Reproductive Medicine and Maternal Health, Orthopaedics and Gastroenterology,” Ragans said. “Among the highlights, we look forward to seeking regulatory approval for what may become the world’s first approved microbiome-based therapy.”
Ragans, who has more than 30 years of experience in the pharmaceutical industry, joined Ferring as vice president of commercial operations in 2012 and was named chief commercial officer in 2016. Before that, he was at Sanofi.
Ragans will be succeeding Paul Navarre, who is leaving the company.
“Brent has been one of the key architects of our U.S. business since joining Ferring eight years ago,” Graff said. “His track record of success, broad background and deep knowledge of Ferring positions him well to lead the company into its next successful chapter.”